Domov › Burkitov lymfóm › Kalifornia

Klinické štúdie Burkitov lymfóm v štáte Kalifornia

20 štúdií pre Burkitov lymfóm hľadá účastníkov v zariadeniach v štáte Kalifornia.

Mestá v štáte Kalifornia

Oficiálny text štúdie (anglicky)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
a 9 ďalších

Prebieha náborFáza 2

366 Days – 46 Years · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Kaiser Permanente-Deer Valley Medical Center, Antioch
Community Cancer Institute, Clovis
UC Irvine Health Cancer Center-Newport, Costa Mesa
a 26 ďalších

Prebieha náborFáza 3

Vek 18 až 39 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
a 1 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
a 4 ďalších

Prebieha náborFáza 2

365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

Prebieha náborFáza 1/2

6 Months – 25 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente-Anaheim, Anaheim
Kaiser Permanente Downey Medical Center, Downey
Kaiser Permanente-Fontana, Fontana
a 14 ďalších

Prebieha náborFáza 2

Vek 1 až 30 · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
a 14 ďalších

Prebieha náborFáza 3

365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

Prebieha náborFáza 2

Vek 7 až 25 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Duarte
Research Site, Los Angeles
Research Site, Palo Alto

Prebieha náborFáza 1/2

Vek 12 a viac · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT06137118

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 8. 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Prebieha náborFáza 1/2

Vek 13 až 90 · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT06533579

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 7. 2026 · NCT07069699

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center, Duarte

Prebieha náborFáza 1

Vek 12 až 55 · Všetky pohlavia · Aktualizované 14. 7. 2026 · NCT07133997

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Duarte

Prebieha náborFáza 1/2

Vek 12 a viac · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT07109219

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT04545762

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
UC San Diego Moores Cancer Center, La Jolla
a 1 ďalších

Prebieha náborFáza 2

Vek 18 až 54 · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06918431

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

City of Hope, Duarte

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 11. 2025 · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

University of California, Los Angeles (UCLA) - Medical Center, Los Angeles

Prebieha náborFáza 1/2

Vek 15 až 50 · Všetky pohlavia · Aktualizované 9. 9. 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
a 2 ďalších

Prebieha náborFáza 2

Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 5. 2025 · NCT03509961

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.